Dash Acquisitions Inc. lifted its stake in Danaher Co. (NYSE:DHR - Free Report) by 5.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 71,531 shares of the conglomerate's stock after buying an additional 3,633 shares during the quarter. Danaher makes up about 4.8% of Dash Acquisitions Inc.'s investment portfolio, making the stock its 8th largest position. Dash Acquisitions Inc.'s holdings in Danaher were worth $19,887,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC raised its holdings in shares of Danaher by 44.5% during the 1st quarter. Ashton Thomas Private Wealth LLC now owns 4,970 shares of the conglomerate's stock worth $1,241,000 after acquiring an additional 1,530 shares in the last quarter. Norden Group LLC bought a new position in Danaher during the first quarter valued at $276,000. J.W. Cole Advisors Inc. grew its stake in shares of Danaher by 41.4% in the 1st quarter. J.W. Cole Advisors Inc. now owns 2,943 shares of the conglomerate's stock worth $735,000 after buying an additional 861 shares in the last quarter. Private Advisor Group LLC increased its holdings in shares of Danaher by 5.2% in the 1st quarter. Private Advisor Group LLC now owns 42,467 shares of the conglomerate's stock worth $10,605,000 after buying an additional 2,085 shares during the last quarter. Finally, Diversify Advisory Services LLC purchased a new stake in shares of Danaher during the 1st quarter valued at about $401,000. 79.05% of the stock is owned by hedge funds and other institutional investors.
NYSE DHR opened at $247.82 on Friday. The company has a market cap of $178.99 billion, a PE ratio of 47.29, a P/E/G ratio of 4.45 and a beta of 0.83. The firm's 50 day moving average price is $266.95 and its 200-day moving average price is $260.37. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a 52-week low of $190.95 and a 52-week high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts' expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business's revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.02 EPS. Sell-side analysts forecast that Danaher Co. will post 7.51 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher's payout ratio is 20.61%.
In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company's stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 11.10% of the company's stock.
DHR has been the subject of several recent research reports. UBS Group dropped their price target on Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Barclays dropped their target price on Danaher from $285.00 to $275.00 and set an "equal weight" rating for the company in a report on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 target price on the stock in a research note on Thursday. Stephens restated an "overweight" rating and issued a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Finally, TD Cowen upped their price target on shares of Danaher from $310.00 to $315.00 and gave the company a "buy" rating in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $287.16.
Check Out Our Latest Research Report on DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.